European CHMP recommends approval of first CAR-T cell medicine (Tecartus) for the treatment of relapsed or refractory mantle cell lymphoma

Tecartus is an autologous T-cell immunotherapy that has been shown to shrink tumours in patients with mantle cell lymphoma which had relapsed or was refractory to other treatment. It is intended for use in adults after ≥2 lines of systemic therapy, including a BTK inhibitor.

Source:

European Medicines Agency